Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

High background in ELISpot assays is associated with elevated levels of immune activation in HIV-1-seronegative individuals in Nairobi.

Liu AY, De Rosa SC, Guthrie BL, Choi RY, Kerubo-Bosire R, Richardson BA, Kiarie J, Farquhar C, Lohman-Payne B.

Immun Inflamm Dis. 2018 Sep;6(3):392-401. doi: 10.1002/iid3.231. Epub 2018 Jul 4.

2.

Validation of a CD1b tetramer assay for studies of human mycobacterial infection or vaccination.

Layton ED, Yu KKQ, Smith MT, Scriba TJ, De Rosa SC, Seshadri C.

J Immunol Methods. 2018 Jul;458:44-52. doi: 10.1016/j.jim.2018.04.004. Epub 2018 Apr 21.

PMID:
29684428
3.

Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10+ Th17 CD4 T-cells differentiate latent from active tuberculosis.

Rakshit S, Adiga V, Nayak S, Sahoo PN, Sharma PK, van Meijgaarden KE, Uk J AJ, Dhar C, Souza GD, Finak G, De Rosa SC, Ottenhoff THM, Vyakarnam A.

Sci Rep. 2017 Sep 20;7(1):11948. doi: 10.1038/s41598-017-10773-5.

4.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov.

5.

RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial.

Moncunill G, De Rosa SC, Ayestaran A, Nhabomba AJ, Mpina M, Cohen KW, Jairoce C, Rutishauser T, Campo JJ, Harezlak J, Sanz H, Díez-Padrisa N, Williams NA, Morris D, Aponte JJ, Valim C, Daubenberger C, Dobaño C, McElrath MJ.

Front Immunol. 2017 Aug 23;8:1008. doi: 10.3389/fimmu.2017.01008. eCollection 2017.

6.

Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells.

Hensel MT, Peng T, Cheng A, De Rosa SC, Wald A, Laing KJ, Jing L, Dong L, Magaret AS, Koelle DM.

J Virol. 2017 Sep 12;91(19). pii: e00810-17. doi: 10.1128/JVI.00810-17. Print 2017 Oct 1.

7.

Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant.

Kanaan SB, Gammill HS, Harrington WE, De Rosa SC, Stevenson PA, Forsyth AM, Allen J, Cousin E, van Besien K, Delaney CS, Nelson JL.

Oncoimmunology. 2017 Mar 31;6(5):e1311436. doi: 10.1080/2162402X.2017.1311436. eCollection 2017.

8.

Vaccination establishes clonal relatives of germinal center T cells in the blood of humans.

Heit A, Schmitz F, Gerdts S, Flach B, Moore MS, Perkins JA, Robins HS, Aderem A, Spearman P, Tomaras GD, De Rosa SC, McElrath MJ.

J Exp Med. 2017 Jul 3;214(7):2139-2152. doi: 10.1084/jem.20161794. Epub 2017 Jun 21.

9.

Controlled Human Malaria Infection Leads to Long-Lasting Changes in Innate and Innate-like Lymphocyte Populations.

Mpina M, Maurice NJ, Yajima M, Slichter CK, Miller HW, Dutta M, McElrath MJ, Stuart KD, De Rosa SC, McNevin JP, Linsley PS, Abdulla S, Tanner M, Hoffman SL, Gottardo R, Daubenberger CA, Prlic M.

J Immunol. 2017 Jul 1;199(1):107-118. doi: 10.4049/jimmunol.1601989. Epub 2017 Jun 2.

10.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.

J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086.

11.

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.

Churchyard G, Mlisana K, Karuna S, Williamson AL, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N, Yu C, Mkhize NN, Hermanus T, Allen M, Pensiero M, Barnett SW, Gray G, Bekker LG, Montefiori DC, Kublin J, Corey L.

PLoS One. 2016 Sep 1;11(9):e0161753. doi: 10.1371/journal.pone.0161753. eCollection 2016.

12.

Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection.

Lama JR, Karuna ST, Grant SP, Swann EM, Ganoza C, Segura P, Montano SM, Lacherre M, De Rosa SC, Buchbinder S, Sanchez J, McElrath MJ, Lemos MP; HVTN 914 Study Team.

PLoS One. 2016 Aug 18;11(8):e0160487. doi: 10.1371/journal.pone.0160487. eCollection 2016.

13.

Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.

Lhomme E, Richert L, Moodie Z, Pasin C, Kalams SA, Morgan C, Self S, De Rosa SC, Thiébaut R.

PLoS One. 2016 Apr 28;11(4):e0152952. doi: 10.1371/journal.pone.0152952. eCollection 2016.

14.

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.

Gray GE, Mayer KH, Elizaga ML, Bekker LG, Allen M, Morris L, Montefiori D, De Rosa SC, Sato A, Gu N, Tomaras GD, Tucker T, Barnett SW, Mkhize NN, Shen X, Downing K, Williamson C, Pensiero M, Corey L, Williamson AL.

Clin Vaccine Immunol. 2016 Jun 6;23(6):496-506. doi: 10.1128/CVI.00717-15. Print 2016 Jun.

15.

Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.

Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, De Rosa SC, Frahm N, Cohen KW, Shukarev G, Orzabal N, van Duijnhoven W, Truyers C, Bachmayer N, Splinter D, Samy N, Pau MG, Schuitemaker H, Luhn K, Callendret B, Van Hoof J, Douoguih M, Ewer K, Angus B, Pollard AJ, Snape MD.

JAMA. 2016 Apr 19;315(15):1610-23. doi: 10.1001/jama.2016.4218.

PMID:
27092831
16.

Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials.

Fiore-Gartland A, Manso BA, Friedrich DP, Gabriel EE, Finak G, Moodie Z, Hertz T, De Rosa SC, Frahm N, Gilbert PB, McElrath MJ.

PLoS One. 2016 Feb 10;11(2):e0147812. doi: 10.1371/journal.pone.0147812. eCollection 2016.

17.

Exploring the feasibility of multi-site flow cytometric processing of gut associated lymphoid tissue with centralized data analysis for multi-site clinical trials.

McGowan I, Anton PA, Elliott J, Cranston RD, Duffill K, Althouse AD, Hawkins KL, De Rosa SC.

PLoS One. 2015 May 26;10(5):e0126454. doi: 10.1371/journal.pone.0126454. eCollection 2015.

18.

Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation.

Rosinski SL, Stone B, Graves SS, Fuller DH, De Rosa SC, Spies GA, Mize GJ, Fuller JT, Storb R.

Transplantation. 2015 Oct;99(10):2083-94. doi: 10.1097/TP.0000000000000744.

19.

OMIP-025: evaluation of human T- and NK-cell responses including memory and follicular helper phenotype by intracellular cytokine staining.

Moncunill G, Dobaño C, McElrath MJ, De Rosa SC.

Cytometry A. 2015 Apr;87(4):289-92. doi: 10.1002/cyto.a.22590. Epub 2014 Nov 18. No abstract available.

20.

OMIP-024: pan-leukocyte immunophenotypic characterization of PBMC subsets in human samples.

Moncunill G, Han H, Dobaño C, McElrath MJ, De Rosa SC.

Cytometry A. 2014 Dec;85(12):995-8. doi: 10.1002/cyto.a.22580. Epub 2014 Oct 28. No abstract available.

21.

OpenCyto: an open source infrastructure for scalable, robust, reproducible, and automated, end-to-end flow cytometry data analysis.

Finak G, Frelinger J, Jiang W, Newell EW, Ramey J, Davis MM, Kalams SA, De Rosa SC, Gottardo R.

PLoS Comput Biol. 2014 Aug 28;10(8):e1003806. doi: 10.1371/journal.pcbi.1003806. eCollection 2014 Aug.

22.

Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials.

Hensley-McBain T, Heit A, De Rosa SC, McElrath MJ, Andersen-Nissen E.

J Immunol Methods. 2014 Sep;411:23-36. doi: 10.1016/j.jim.2014.06.002. Epub 2014 Jun 9.

23.

Optimizing viable leukocyte sampling from the female genital tract for clinical trials: an international multi-site study.

McKinnon LR, Hughes SM, De Rosa SC, Martinson JA, Plants J, Brady KE, Gumbi PP, Adams DJ, Vojtech L, Galloway CG, Fialkow M, Lentz G, Gao D, Shu Z, Nyanga B, Izulla P, Kimani J, Kimwaki S, Bere A, Moodie Z, Landay AL, Passmore JA, Kaul R, Novak RM, McElrath MJ, Hladik F.

PLoS One. 2014 Jan 15;9(1):e85675. doi: 10.1371/journal.pone.0085675. eCollection 2014.

24.

Enhanced and efficient detection of virus-driven cytokine expression by human NK and T cells.

Pattacini L, Murnane PM, Fluharty TR, Katabira E, De Rosa SC, Baeten JM, Lund JM.

J Virol Methods. 2014 Apr;199:17-24. doi: 10.1016/j.jviromet.2014.01.003. Epub 2014 Jan 10.

25.

High-throughput flow cytometry data normalization for clinical trials.

Finak G, Jiang W, Krouse K, Wei C, Sanz I, Phippard D, Asare A, De Rosa SC, Self S, Gottardo R.

Cytometry A. 2014 Mar;85(3):277-86. doi: 10.1002/cyto.a.22433. Epub 2013 Dec 31.

26.

Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity.

Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, Krishnamurty AT, Chang JT, Adams DJ, Hensley TR, Salter AI, Morgan CA, Duerr AC, De Rosa SC, Aderem A, McElrath MJ.

Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):E3503-12. doi: 10.1073/pnas.1208972109. Epub 2012 Nov 14.

27.

OMIP-014: validated multifunctional characterization of antigen-specific human T cells by intracellular cytokine staining.

De Rosa SC, Carter DK, McElrath MJ.

Cytometry A. 2012 Dec;81(12):1019-21. doi: 10.1002/cyto.a.22218. Epub 2012 Oct 18. No abstract available.

28.

Enumeration of major peripheral blood leukocyte populations for multicenter clinical trials using a whole blood phenotyping assay.

Hensley TR, Easter AB, Gerdts SE, De Rosa SC, Heit A, McElrath MJ, Andersen-Nissen E.

J Vis Exp. 2012 Sep 16;(67):e4302. doi: 10.3791/4302.

29.

HIV-1-specific enzyme-linked immunosorbent spot assay responses in HIV-1-exposed uninfected partners in discordant relationships compared to those in low-risk controls.

Guthrie BL, Lohman-Payne B, Liu AY, Bosire R, Nuvor SV, Choi RY, Mackelprang RD, Kiarie JN, De Rosa SC, Richardson BA, John-Stewart GC, Farquhar C.

Clin Vaccine Immunol. 2012 Nov;19(11):1798-805. doi: 10.1128/CVI.00179-12. Epub 2012 Sep 12.

30.

Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation.

McClure J, Lovelace ES, Elahi S, Maurice NJ, Wagoner J, Dragavon J, Mittler JE, Kraft Z, Stamatatos L, Horton H, De Rosa SC, Coombs RW, Polyak SJ.

PLoS One. 2012;7(7):e41832. doi: 10.1371/journal.pone.0041832. Epub 2012 Jul 25. Erratum in: PLoS One. 2012;7(10). doi: 10.1371/annotation/78ba072a-6b7a-430a-8fcd-ef020e4fc458. Stamatatos, Leonidis [corrected to Stamatatos, Leonidas].

31.

Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells.

Defawe OD, Fong Y, Vasilyeva E, Pickett M, Carter DK, Gabriel E, Rerks-Ngarm S, Nitayaphan S, Frahm N, McElrath MJ, De Rosa SC.

J Immunol Methods. 2012 Aug 31;382(1-2):117-28. doi: 10.1016/j.jim.2012.05.011. Epub 2012 May 22.

32.

A brilliant new addition to the fluorescent probe toolbox.

De Rosa SC.

Cytometry A. 2012 Jun;81(6):445-6. doi: 10.1002/cyto.a.22036. Epub 2012 Apr 6. No abstract available.

33.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH.

N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.

34.

DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.

Gorse GJ, Newman MJ, deCamp A, Hay CM, De Rosa SC, Noonan E, Livingston BD, Fuchs JD, Kalams SA, Cassis-Ghavami FL; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2012 May;19(5):649-58. doi: 10.1128/CVI.00038-12. Epub 2012 Mar 7.

35.

Vaccine applications of flow cytometry.

De Rosa SC.

Methods. 2012 Jul;57(3):383-91. doi: 10.1016/j.ymeth.2012.01.001. Epub 2012 Jan 10. Review.

36.

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.

Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, Casimiro DR, Duerr A, Robertson MN, Buchbinder SP, Huang Y, Spies GA, De Rosa SC, McElrath MJ.

J Clin Invest. 2012 Jan;122(1):359-67. doi: 10.1172/JCI60202. Epub 2011 Dec 27.

37.

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network.

PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3.

38.

HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.

De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, Morgan C, Kalams SA, Tomaras GD, Akondy R, Ahmed R, Lau CY, Graham BS, Nabel GJ, McElrath MJ; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network.

J Immunol. 2011 Sep 15;187(6):3391-401. doi: 10.4049/jimmunol.1101421. Epub 2011 Aug 15.

39.

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ; HIV Vaccine Trials Network of NIAID.

J Infect Dis. 2011 Apr 15;203(8):1165-73. doi: 10.1093/infdis/jiq175.

40.

Association between peripheral γδ T-cell profile and disease progression in individuals infected with HIV-1 or HIV-2 in West Africa.

Zheng NN, McElrath MJ, Sow PS, Mesher A, Hawes SE, Stern J, Gottlieb GS, De Rosa SC, Kiviat NB.

J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):92-100. doi: 10.1097/QAI.0b013e318215a877.

PMID:
21423026
41.

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2011 Feb 24;29(10):1948-58. doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7.

42.

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).

Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De Rosa SC, McElrath MJ; NIAID HIV Vaccine Trials Network.

PLoS One. 2010 Oct 27;5(10):e13579. doi: 10.1371/journal.pone.0013579.

43.

Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes.

Laing KJ, Magaret AS, Mueller DE, Zhao L, Johnston C, De Rosa SC, Koelle DM, Wald A, Corey L.

J Clin Immunol. 2010 Sep;30(5):703-22. doi: 10.1007/s10875-010-9441-2. Epub 2010 Jul 16.

44.

ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans.

Jing L, McCaughey SM, Davies DH, Chong TM, Felgner PL, De Rosa SC, Wilson CB, Koelle DM.

J Immunol Methods. 2009 Aug 15;347(1-2):36-45. doi: 10.1016/j.jim.2009.05.011. Epub 2009 Jun 9.

45.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.

46.

The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression.

Chattopadhyay PK, Betts MR, Price DA, Gostick E, Horton H, Roederer M, De Rosa SC.

J Leukoc Biol. 2009 Jan;85(1):88-97. doi: 10.1189/jlb.0208107. Epub 2008 Oct 10.

47.

Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials.

Shulman N, Bellew M, Snelling G, Carter D, Huang Y, Li H, Self SG, McElrath MJ, De Rosa SC.

Cytometry A. 2008 Sep;73(9):847-56. doi: 10.1002/cyto.a.20600.

48.

Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach.

McLaughlin BE, Baumgarth N, Bigos M, Roederer M, De Rosa SC, Altman JD, Nixon DF, Ottinger J, Oxford C, Evans TG, Asmuth DM.

Cytometry A. 2008 May;73(5):400-10. doi: 10.1002/cyto.a.20555.

49.

Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part II: Panel performance across different instrument platforms.

McLaughlin BE, Baumgarth N, Bigos M, Roederer M, De Rosa SC, Altman JD, Nixon DF, Ottinger J, Li J, Beckett L, Shacklett BL, Evans TG, Asmuth DM.

Cytometry A. 2008 May;73(5):411-20. doi: 10.1002/cyto.a.20556.

50.

Gamma delta+ T cells involvement in viral immune control of chronic human herpesvirus 8 infection.

Barcy S, De Rosa SC, Vieira J, Diem K, Ikoma M, Casper C, Corey L.

J Immunol. 2008 Mar 1;180(5):3417-25.

Supplemental Content

Loading ...
Support Center